For full list of the lab’s publications click here.

Recent publications:

Retinoic acid and vitamin A related:

Stereoselective formation and metabolism of 4-hydroxy-retinoic Acid enantiomers by cytochrome p450 enzymes. Shimshoni JA, Roberts AG, Scian M, Topletz AR, Blankert SA, Halpert JR, Nelson WL, Isoherranen N. J Biol Chem. 2012 Dec 7;287(50):42223-32.

A sensitive and specific method for measurement of multiple retinoids in human serum with UHPLC-MS/MS. Arnold SL, Amory JK, Walsh TJ, Isoherranen N. J Lipid Res. 2012 Mar;53(3):587-98.

Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases. Topletz AR, Thatcher JE, Zelter A, Lutz JD, Tay S, Nelson WL, Isoherranen N. Biochem Pharmacol. 2012 Jan 1;83(1):149-63.

The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. Thatcher JE, Zelter A, Isoherranen N. Biochem Pharmacol. 2010 Sep 15;80(6):903-12.

Drug disposition during pregnancy related:

Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Isoherranen N, Thummel KE. Drug Metab Dispos. 2013 Feb;41(2):256-62.

Hepatic Cyp2d and Cyp26a1 mRNAs and activities are increased during mouse pregnancy. Topletz AR, Le HN, Lee N, Chapman JD, Kelly EJ, Wang J, Isoherranen N. Drug Metab Dispos. 2013 Feb;41(2):312-9.

Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy. Dickmann LJ, Isoherranen N. Drug Metab Dispos. 2013 Feb;41(2):270-4.

In the area of Drug-drug interactions:

Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems. Lutz JD, VandenBrink BM, Babu KN, Nelson WL, Kunze KL, Isoherranen N. Drug Metab Dispos. 2013 Dec;41(12):2056-65.

Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N. Drug Metab Dispos. 2013 Jul;41(7):1414-24.

Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I. Chem Res Toxicol. 2012 Nov 19;25(11):2285-300.

Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, Isoherranen N. Clin Pharmacol Ther. 2011 Jun;89(6):888-95.

Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Yeung CK, Fujioka Y, Hachad H, Levy RH, Isoherranen N. Clin Pharmacol Ther. 2011 Jan;89(1):105-13.